ASA	American society of Anesthesiologists
ATZ/BEV	atezolizumab/bevacizumab
BCLC	Barcelona Clinic Liver Cancer
BIA	bioimpedance analysis
BMI	body mass index
CLD	chronic liver disease
CSPH	clinical significant portal hypertension
CT	computed tomography
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
cTACE	conventional transarterial chemoembolization
DEB-TACE	drug-eluting beads transarterial chemoembolization
DXA	dual energy X-ray absorptiometry
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
ICI	immune checkpoint inhibitors
IGF-1	insulin-like growth factor-1
IMAC	intramuscular adipose tissue content
IMAT	intramuscular adipose tissue
LEN	lenvatinib
LSN	liver surface nodularity
MASLD	metabolic-dysfunction associated steatotic liver disease
MRI	magnetic resonance imaging
mTOR	mammalian target of rapamycin
MWA	microwave ablation
OLT	orthotopic liver transplantation
OS	overall survival
PD1	programed cell death 1
PDL-1	programed death ligand-1
PFS	progression-free survival
PMI	psoas muscle index
PNI	prognostic nutritional index
RFA	radiofrequency ablation
RFS	recurrence free survival
ROS	reactive oxygen species
SBRT	stereotactic body radiotherapy
SIRT	selective internal radiation therapy
SMI	skeletal muscle index
TACE	transarterial chemoembolization
TAE	transarterial embolization
TARE	transarterial radioembolization
T2DM	type 2 diabetes mellitus
TKIs	tyrosine kinase inhibitors
UCSF	University of California San Francisco
VEGF	vascular endothelial growth factor
VFA	visceral fat area
Y90	Yttrium90